The U.S. Food and Drug Administration (FDA) announced the approval of the first generic version of Climara Pro on October 20, 2026. The generic product, known as the estradiol and levonorgestrel transdermal system, was approved by Zydus Pharmaceuticals (USA) Inc.
The generic patch is therapeutically equivalent to Climara Pro, a transdermal hormone therapy patch indicated for women with an intact uterus. The approval allows for once-weekly application of the medication. Climara Pro and its generic counterpart contain both estrogen and progestogen in a single patch, a formulation that differs from estrogen-only patches commonly used in menopause treatment.
The FDA indicated that the progestogen component is included to reduce the risk of endometrial hyperplasia that can occur with estrogen use alone. The generic patch is contraindicated for patients with undiagnosed abnormal genital bleeding, breast cancer or a history of breast cancer, estrogen-dependent neoplasia, active deep vein thrombosis (DVT), pulmonary embolism (PE), active arterial thromboembolic disease, known anaphylactic reaction or angioedema, hypersensitivity to estradiol and levonorgestrel, hepatic impairment, or protein C, protein S, or antithrombin deficiency.
The most common adverse reactions reported in clinical trials, occurring in 5 percent or more of patients, include application site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache, and flu syndrome.
The FDA noted that menopause is a universal experience for women that can affect quality of life. The agency highlighted that increasing the availability of generic drugs helps create competition in the marketplace, which can help make treatment more affordable and increase access to healthcare for more patients.
